During the past decade, Amir Malik Research conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 3 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Amir Malik Research" are "Cardiovascular Disease" (2 trials), "Acute Coronary Syndrome" (1 trials), "Atrial Fibrillation" (1 trials), "Coronary Artery Disease" (1 trials) and "Myocardial Infarction" (1 trials). Many other conditions were trialed in "Amir Malik Research" in a lesser frequency.

Most popular intervention types in "Amir Malik Research" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "bococizumab (PF-04950615)" (2 trials), "CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin" (1 trials) and "Plavix (clopidogrel 75 mg) and aspirin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Amir Malik Research" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Amir Malik Research". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Amir Malik Research, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Amir Malik Research, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".